ARDX

Ardelyx, Inc.

9.53 USD
-0.14 (-1.45%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ardelyx, Inc. stock is up 0.95% since 30 days ago. The next earnings date is May 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Feb 14:51 17 Jan, 2025 10.00 PUT 100 756
26 Feb 14:55 17 Jan, 2025 7.50 PUT 325 4226
26 Feb 14:59 17 Jan, 2025 2.50 CALL 45 466
26 Feb 15:06 17 Jan, 2025 10.00 PUT 140 756
26 Feb 15:06 17 Jan, 2025 10.00 PUT 100 756
26 Feb 15:22 17 Jan, 2025 10.00 CALL 159 2454
27 Feb 15:23 18 Oct, 2024 8.00 CALL 100 10
27 Feb 15:50 18 Oct, 2024 14.00 CALL 318 0
28 Feb 14:53 19 Apr, 2024 5.00 CALL 100 916
28 Feb 15:09 22 Mar, 2024 10.00 CALL 468 96

About Ardelyx, Inc.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation. It is also developing RDX013, a potassium secretagogue, for the. treatment of elevated serum potassium, or hyperkalemia, among certain patients with kidney and/or heart disease.

  • Piper Sandler
    Fri Feb 23, 13:31
    buy
    confirm
  • Wedbush
    Fri Feb 23, 08:02
    buy
    confirm